

Member's Last Name:

Revlimid

Express Scripts
Prior Authorization
Phone 1-844-424-8886
Fax 1-877-251-5896

To start your Part D Coverage Determination request, you (or your representative or your doctor or other prescriber) should contact Express Scripts, Inc (ESI):

- You may Call ESI at 1-844-424-8886, 24 hours a day, 7 days a week, TTY users: 1-800-716-3231
- You may Fax your request to: 1-877-251-5896 (Attention: Medicare Reviews)
- You may also send your request via email to: medicarepartdparequests@express-scripts.com

Member's First Name:

	SCAN ID num	ber:	Date of Birth:	
	Prescriber's N	ame:	Contact Person:	
	Office phone:		Office Fax:	
	Medication:		Diagnosis:	
	SECTION A	Please answer the following	ng questions	
1. 2.		Is the member currently taking Is the diagnosis or indication for (If No, skip to question 4.)	g the requested medication? for the treatment of mantle cell lymphoma (MCL)?	
3.	θ Yes θ No	Is there documentation of disease relapse or progression on at least two prior therapies including bortezomib prior to the initiation of Revlimid?		
4.	θ Yes θ No	Is the diagnosis or indication for the treatment of transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS)? (If No, skip to question 6.)		
5.	θ Yes θ No	Is the disease associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities confirmed by testing?		
6.	θ Yes θ No	Is the diagnosis or indication for the treatment of chronic lymphocytic leukemia (CLL)? (If No, skip to question 8.)		
7.	θ Yes θ No	Is the patient in a controlled clinical trial?		
8.	θ Yes θ No	Is the diagnosis or indication for the treatment of multiple myeloma? (If No, skip to question 11.)		
9.	θ Yes θ No	Is Revlimid being used in com question 13.)	nbination with dexamethasone? (If Yes, skip to	

10. θ Yes θ No	Is Revlimid being used as maintenance therapy			
44	hematopoietic stem cell transplantation (auto-F	, , , , , , , , , , , , , , , , , , , ,		
11. θ Yes θ No	Is the diagnosis or indication for the treatment	of follicular lymphoma, in		
40 0 14 0 14	combination with a rituximab product?			
12. θ Yes θ No	Is the diagnosis or indication for the treatment	or marginal zone lymphoma, in		
40 0 W 0 N	combination with a rituximab product?			
13. θ Yes θ No	Is the prescription written or recommended by			
14. θ Yes θ No	Is the member a female of reproductive potenti	al? (If No, skip question 15)		
15. θ Yes θ No	Is the member pregnant?			
Please document the symptoms and/or any other information important to this review:				
SECTION B	Physician Signature			
	PHYSICIAN SIGNATURE	DATE		

FAX COMPLETED FORM TO: 1-877-251-5896

Our response time for prescription drug coverage standard requests is 72 hours. If you or your prescriber believe that waiting 72 hours for a standard decision could seriously harm your life, health, or ability to regain maximum function, you can ask for an expedited (fast) decision. If your prescriber indicates that waiting 72 hours could seriously harm your health, we will automatically give you a decision within 24 hours. If you do not obtain your prescriber's support for an expedited request, we will decide if your case requires a fast decision. You cannot request an expedited coverage determination if you are asking us to pay you back for a drug you already received. View our formulary and Prior Authorization criteria online at http://www.scanhealthplan.com